Danaher Corporation
DHR
Below: live stock price for Danaher Corporation (DHR), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Danaher Corporation (DHR) is a Healthcare company based in United States. Operating in Diagnostics & Research, it employs about 58,000 people. Over the past year DHR traded between 160.93 and 242.8 USD. Trailing P/E sits near 38.45 on a market cap of about 163.25B USD. It currently yields 0.69% in dividends.
- Prev close
- $236.98
- Volume (24h)
- $870.86M
- Market cap
- $163.25B
- Currency
- USD
Score
54/ 100 · Mixed
- Value45
- Quality60
- Momentum39
- Growth54
- Risk85
- Dividend52
- Liquidity42
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 234.1752 +0.84%
- +20 bars
- 236.8859 +2.00%
- +60 bars
- 237.943 +2.46%
- +120 bars
- 237.9818 +2.48%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±1.83% per bar.
Interpretation
Composite signals look mixed. Strength: risk profile with weakness: momentum. Price sits near the upper third of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value45/100
Value looks mixed — driven by P/E (38.45).
P/E:38.45P/B:3.05PEG:1.35 - Quality60/100
Quality looks solid — driven by Gross margin (59.36%).
ROE:8.19%ROA:4.06%Profit margin:16.91%Gross margin:59.36% - Momentum39/100
Momentum looks weak — driven by 52w change (8.49%).
52w change:8.49% - Growth54/100
Growth looks mixed — driven by Earnings growth (37.80%).
Revenue growth:8.30%Earnings growth:37.80% - Risk85/100
Risk looks strong — driven by Debt / equity (51.8).
Beta:0.8Debt / equity:51.8Short interest:1.30% - Dividend52/100
Dividend looks mixed — driven by Payout ratio (25.17%).
Dividend yield:0.69%Payout ratio:25.17% - Liquidity42/100
Liquidity looks weak — driven by Current ratio (1.63).
Current ratio:1.63Quick ratio:1.19
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 251 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 30.4%
- Max drawdown
- -33.1%
- Below period high
- -4.4%
- Best day
- +7.46%
- Worst day
- -10.99%
- Up days
- 52%
- Current streak
- 1 down
- Typical day swing
- 2.6%
- Volume vs average
- +28%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 238.46 high → 198.44 low · 60 bars
- ResistanceFib +161.8% extensionnot reached303.2124 USD+30.57% from current
- ResistanceFib +100% extensionnot reached278.48 USD+19.92% from current
- ResistanceFib +61.8% extensionnot reached263.1924 USD+13.33% from current
- ResistanceFib +27.2% extensionnot reached249.3454 USD+7.37% from current
- Current232.23 USD
- SupportFib 23.6% retracementNearesttested 6×229.0153 USD-1.38% from current
- SupportFib 38.2% retracementtested 10×223.1724 USD-3.90% from current
- SupportFib 50% midpointtested 10×218.45 USD-5.93% from current
- SupportFib 61.8% retracementtested 14×213.7276 USD-7.97% from current
- SupportFib 78.6% retracementtested 13×207.0043 USD-10.86% from current
- SupportFib −27.2% extensionnot reached187.5546 USD-19.24% from current
- SupportFib −61.8% extensionnot reached173.7076 USD-25.20% from current
- SupportFib −100% extensionnot reached158.42 USD-31.78% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $242.80
- 52w low
- $160.93
- 52w change
- 8.49%
- Day high
- $238.38
- Day low
- $230.46
- P/E (TTM)
- 38.45
- Forward P/E
- 24.92
- PEG
- 1.35
- Price / Book
- 3.05
- Beta (5Y)
- 0.8
- Enterprise value
- 185.49B
- EV / Revenue
- 7.24
- EV / EBITDA
- 22.47
- EPS (TTM)
- $6.04
- Forward EPS
- $9.32
- Dividend yield
- 0.69%
- Dividend rate
- $1.60
- Payout ratio
- 25.17%
- Revenue (TTM)
- 25.61B
- EBITDA
- 8.26B
- Free cash flow
- 4.75B
- Total cash
- 5.68B
- Total debt
- 27.78B
- Debt / Equity
- 51.8
- Current ratio
- 1.63
- Quick ratio
- 1.19
- Profit margin
- 16.91%
- Gross margin
- 59.36%
- Return on assets
- 4.06%
- Return on equity
- 8.19%
- Shares outstanding
- 702.99M
- Float
- 626.33M
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- Beta (vs S&P 500)
- 0.8
- less volatile
- 52-week change
- 8.49%
- Short % of float
- 1.30%
- Short ratio (days)
- 1.76
- Debt / Equity
- 51.8
- very high leverage
- Current ratio
- 1.63
- Quick ratio
- 1.19
- ROE
- 8.19%
- ROA
- 4.06%
- PEG ratio
- 1.35
- EV / Revenue
- 7.24
- EV / EBITDA
- 22.47
- Revenue growth
- 8.30%
- Earnings growth
- 37.80%
- EBITDA
- 8.26B
- Free cash flow
- 4.75B
- Total cash
- 5.68B
- Total debt
- 27.78B
- Insider holdings
- 10.81%
- Institutional
- 83.64%
Recent rating changes
- 2026-10-22CitigroupBuy → Buymain
- 2026-10-22BarclaysOverweight → Overweightmain
- 2026-10-22JP MorganOverweight → Overweightmain
- 2026-10-22TD CowenBuy → Buymain
- 2026-10-22StifelBuy → Buymain
- 2026-10-22BairdOutperform → Outperformmain
- 2026-10-13Morgan StanleyOverweight → Overweightmain
- 2026-10-13TD CowenBuy → Buymain
Financial documents
- Corporate Changes & Voting Matters8-K2026-10-21
- Corporate Changes & Voting Matters8-K2026-10-13
- Notification filed by national security exchange to report the removal from listing and registration of matured25-NSE2026-09-30
- Corporate Changes & Voting Matters8-K2026-08-03
- Periodic Financial Reports10-Q2026-07-21
- Annual report of employee stock purchase11-K2026-06-16
- Offering RegistrationsS-82026-06-09
- Corporate Changes & Voting Matters8-K2026-06-03
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-05-12
- Corporate Changes & Voting Matters8-K2026-05-07
- Corporate Changes & Voting Matters8-K2026-04-29
- Corporate Changes & Voting Matters8-K2026-04-21
Recent news
- Point-of-Care International Normalized Ratio (INR) Testing Market Report 2026 | Secure 10.1% CAGR Gains as Abbott, Roche, Danaher and Siemens Healthineers Scale Home MonitoringGlobeNewswireyesterday
- The Case Against a SpaceX and Tesla MergerMotley Foolyesterday
- Why Josh Kushner’s Firm Just Spent $7.6 Billion on a 150-Year-Old CompanyThe Wall Street Journalyesterday
- Danaher Corp Insider Sold Shares Worth $7,014,244, According to a Recent SEC FilingMT Newswiresyesterday
- Danaher Corp Insider Sold Shares Worth $1,782,157, According to a Recent SEC FilingMT Newswiresyesterday
- Repligen Soars 5% as RBC Raises Price Target to $200 After Full-Year Guidance HikeTIKR2 days ago
- AI in Pathology Market Size, Share, Trends, and Global Forecast 2026-2036 | A $1.72 Billion Opportunity Featuring Profiles of Key Players Leica Biosystems (Danaher), Roche, Hamamatsu Photonics, Fujifilm, Agilent TechnologiesGlobeNewswire2 days ago
- Molecular Spectroscopy - Global Strategic Business Report: Capitalize on the Surge to $8.7 Billion by 2032 as Agilent, Bruker, Danaher, and Thermo Fisher Scientific Accelerate AI-Driven AnalysisGlobeNewswire2 days ago
Related
Other assets in this category.
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.